Product Information
OXCARBAZEPINE ER 600 MG TABLET is a generic product labeled by Apotex Corp., priced at $9.5783 per EA under NDC 60505413007. Its NADAC has been published 98 times since Nov 20, 2024.
FDA first approved this application on Jul 13, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the OXCARBAZEPINE market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
600 mg/1
Manufacturer
Apotex Corp.NDC
60505413007
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
OXCARBAZEPINEApproval Type
Generic (ANDA)
FDA Application
ANDA213369FDA Approved
7/13/2023
TE Code
AB
On Market Since
9/3/2024
Pharmacological Classes
Price Statistics
The NADAC for OXCARBAZEPINE ER 600 MG TABLET has been published 98 times since Nov 20, 2024, and over the history we have for it it has declined 42.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $9.5783 per EA |
|---|---|
| All-time high | $17.4978 (Sep 10, 2025) |
| All-time low | $9.4168 (Jul 22, 2026) |
| 52-week high | $16.6183 |
| 52-week low | $9.4168 |
| Median price | $15.7016 |
| Average price | $14.5739 |
| Largest weekly change | -12.5% (Feb 18, 2026) |
| Weeks tracked | 98 |
| Tracking since | Nov 20, 2024 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 97% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Apotex Corp. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
OXCARBAZEPINE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anti-epileptic Agent class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OXCARBAZEPINE ER 600 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for OXCARBAZEPINE ER 600 MG TABLET, manufactured by Apotex Corp., is $9.5783 per EA (NDC 60505413007), effective Sep 30, 2026.
How has the price of OXCARBAZEPINE ER 600 MG TABLET changed over time?
Over the history we have for it, the NADAC for OXCARBAZEPINE ER 600 MG TABLET has declined 42.7%. It has been tracked across 98 weekly CMS publications since Nov 20, 2024.
What are the highest and lowest recorded NADAC prices for OXCARBAZEPINE ER 600 MG TABLET?
Since Nov 20, 2024, the NADAC for OXCARBAZEPINE ER 600 MG TABLET has ranged from a low of $9.4168 (Jul 22, 2026) to a high of $17.4978 (Sep 10, 2025), with a median of $15.7016 per EA.
Are there cheaper alternatives to OXCARBAZEPINE ER 600 MG TABLET?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, OXCARBAZEPINE 600 MG TABLET, is $0.3170 per EA — about 97% below OXCARBAZEPINE ER 600 MG TABLET.
Who manufactures OXCARBAZEPINE ER 600 MG TABLET?
OXCARBAZEPINE ER 600 MG TABLET (NDC 60505413007) is labeled by Apotex Corp., and CMS classifies it as a generic product.